Role of Stat3 in Regulating p53 Expression and Function
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Loss of p53 function by mutation is common in cancer. However, most natural p53 mutations occur at a late stage in tumor development, and many clinically detectable cancers have reduced p53 expression but no p53 mutations. It remains to be fully determined what mechanisms disable p53 during malignant initiation and in cancers without mutations that directly affect p53. We show here that oncogenic signaling pathways inhibit the p53 gene transcription rate through a mechanism involving Stat3, which binds to the p53 promoter in vitro and in vivo. Site-specific mutation of a Stat3 DNA-binding site in the p53 promoter partially abrogates Stat3-induced inhibition. Stat3 activity also influences p53 response genes and affects UV-induced cell growth arrest in normal cells. Furthermore, blocking Stat3 in cancer cells up-regulates expression of p53, leading to p53-mediated tumor cell apoptosis. As a point of convergence for many oncogenic signaling pathways, Stat3 is constitutively activated at high frequency in a wide diversity of cancers and is a promising molecular target for cancer therapy. Thus, repression of p53 expression by Stat3 is likely to have an important role in development of tumors, and targeting Stat3 represents a novel therapeutic approach for p53 reactivation in many cancers lacking p53 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“In particular, Stat3 signaling is usually proproliferative and antiapoptiotic (50), whereas wild-type p53 is typically antiproliferative and proapoptotic (35, 44 ).”
BackgroundDarnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 2×
“As a point of convergence for many growth and cytokine signaling pathways (13, 41) that are commonly overactive in tumor cells, Stat3 is constitutively activated with high frequency in diverse cancers (4, 12, 50), suggesting that repression of p53 expression by Stat3 is also likely to have a role in tumor development.”
BackgroundThe E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 6×
“As a point of convergence for many growth and cytokine signaling pathways (13, 41) that are commonly overactive in tumor cells, Stat3 is constitutively activated with high frequency in diverse cancers (4, 12, 50), suggesting that repression of p53 expression by Stat3 is also likely to have a role in tumor development.”
BackgroundSelf-citationChromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,260
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 1×
“The binding of Stat3 to the p53 promoter as detected by the p53(-218) probe is relatively weak, which is not surprising as individual natural STAT-binding sites often have weak binding activity (32, 47, 48).”
BackgroundSelf-citationThe role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201 · cited 1×
“As a point of convergence for many growth and cytokine signaling pathways (13, 41) that are commonly overactive in tumor cells, Stat3 is constitutively activated with high frequency in diverse cancers (4, 12, 50), suggesting that repression of p53 expression by Stat3 is also likely to have a role in tumor development.”
BackgroundTranscription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194 · cited 3×
“ber of human cancers (12), we explored their role in the sup-”
BackgroundRegulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Self-citationSite-directed mutagenesis of virtually any plasmid by eliminating a unique site
Deng, W. P., & Nickoloff, J. A. (1992) · Analytical Biochemistry · doi:10.1016/0003-2697(92)90280-k · Cited by 1,060
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 3×
“Stat3 is one of the critical downstream targets of active Src tyrosine kinase (5, 42, 49 ).”
BackgroundMethodSelf-citationMapping of the p53 and mdm-2 interaction domains.
Chen, J., Marechal, V, & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689
Self-citationStat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651
Self-citationStat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
The SIF binding element confers sis/PDGF inducibility onto the c‐fos promoter.
Wagner, B. J., Hayes, T. E., Hoban, C. J., & Cochran, B. H. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07898.x · Cited by 592 · cited 1×
“hSIE, a high-affinity variant of the STAT-binding site in the c-fos promoter (45), also effectively competed for the protein in the DNA/protein complex.”
BackgroundWild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579 · cited 1×
“Indeed, it has been shown that the oncogenic potential of simian virus 40 (SV40) large T antigen depends on its ability to negatively regulate p53 activity, providing a mechanism by which oncoproteins inhibit p53 function in the absence of p53 mutations (3, 16, 34, 38).”
BackgroundNakajima, K., Yamanaka, Y., Nakae, K., Kojima, H., Ichiba, M., Kiuchi, N., Kitaoka, T., Fukada, T., Hibi, M., & Hirano, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00734.x · Cited by 565
Transcriptional control in the production of liver-specific mRNAs
Derman, E., Krauter, K., Walling, L., Weinberger, C., Ray, M., & Darnell Jr., J. E. (1981) · Cell · doi:10.1016/0092-8674(81)90436-0 · Cited by 550
Xie, T.-X., Wei, D., Liu, M., Gao, A. C., Ali-Osman, F., Sawaya, R., & Huang, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207383 · Cited by 550
Compromised HOXA5 function can limit p53 expression in human breast tumours
Raman, V., Martensen, S. A., Reisman, D., Evron, E., Odenwald, W. F., Jaffee, E., Marks, J., & Sukumar, S. (2000) · Nature · doi:10.1038/35016125 · Cited by 482
Xu, X., Sun, Y.-L., & Hoey, T. (1996) · Science · doi:10.1126/science.273.5276.794 · Cited by 480
Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., & Jove, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107527200 · Cited by 448
Self-citationSeidel, H. M., Milocco, L. H., Lamb, P., Darnell, J. E., Stein, R. B., & Rosen, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.3041 · Cited by 415
Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 342
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
Pharoah, P. D. P., Day, N. E., & Caldas, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690628 · Cited by 308
Cooperation between STAT3 and c-Jun Suppresses Fas Transcription
Ivanov, V. N., Bhoumik, A., Krasilnikov, M., Raz, R., Owen-Schaub, L. B., Levy, D., Horvath, C. M., & Ronai, Z. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00199-x · Cited by 248
Bargonetti, J., Reynisdóttir, I., Friedman, P. N., & Prives, C. (1992) · Genes & Development · doi:10.1101/gad.6.10.1886 · Cited by 223
McLemore, M. L., Grewal, S., Liu, F., Archambault, A., Poursine-Laurent, J., Haug, J., & Link, D. C. (2001) · Immunity · doi:10.1016/s1074-7613(01)00101-7 · Cited by 209
Role of T antigen interactions with p53 in tumorigenesis
Pipas, J. M., & Levine, A. J. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0343 · Cited by 199
Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis
Zhang, Y.-W., Wang, L.-M., Jove, R., & Vande Woude, G. F. (2002) · Oncogene · doi:10.1038/sj.onc.1205004 · Cited by 196
Self-citationOverexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells.
Johnson, P. J., Coussens, P. M., Danko, A. V., & Shalloway, D. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.5.1073 · Cited by 168
Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
Chen, L., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.195 · Cited by 159
Self-citationNiu, G., Shain, K. H., Huang, M., Ravi, R. K., Bedi, A., Dalton, W. S., Jove, R., & Yu, H. (2001) · PubMed · Cited by 142
Self-citationBroome, M. A., & Hunter, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.28.16798 · Cited by 136
c‐Abl is an effector of Src for growth factor‐induced c‐myc expression and DNA synthesis
Furstoss, O., Dorey, K., Simon, V., Barilà, D., Superti‐Furga, G., & Roche, S. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.514 · Cited by 128
A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein
Freedman, D. A., Epstein, C. B., Roth, J. C., & Levine, A. J. (1997) · Molecular Medicine · doi:10.1007/bf03401678 · Cited by 113
Lin, J., Tang, H., Jin, X., Jia, G., & Hsieh, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205426 · Cited by 109
Liu, C., Smith, B. M., Ajito, K., Komatsu, H., Gomez‐Paloma, L., Li, T., Theodorakis, E. A., Nicolaou, K. C., & Vogt, P. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.2.940 · Cited by 54
Lin, J., Jin, X., Rothman, K., Lin, H.-J., Tang, H., & Burke, W. M. (2002) · PubMed · Cited by 52
Broome, M. A., & Courtneidge, S. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203608 · Cited by 44
Positive and negative regulatory elements in the murine p53 promoter.
Roy, B., & Reisman, D. (1996) · PubMed · Cited by 12
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Self-citationDangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., & Stark, G. R. (2007) · Genes & Development · doi:10.1101/gad.1553707 · Cited by 611
“STAT3 also functions as a transcriptional repressor of p53 expression: Blocking STAT3 in cancer cells up-regulates the expression of p53, leading to p53-mediated apoptosis (Niu et al. 2005).”
Background
Metadata
- Authors
- Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., Jove, R., Chen, J., & Yu, H.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2005-09-01
- Volume
- 25
- Issue
- 17
- Pages
- 7432-7440
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2114445658
- Cited by
- 392
- References
- 51
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.